Study Shows COVID-19 Vaccines Lose Efficacy Over Time

Study Shows COVID-19 Vaccines Lose Efficacy Over Time
TradeGM Analysis date_range August 19th, 2021

An Oxford University public health study has found that the two most commonly used COVID-19 vaccines lose their efficacy over time. According to the report, the Pfizer-BioNTech and AstraZeneca vaccines are much less effective against the dominant Delta variant after three months of being administered.

Investigating the Efficacy of Vaccines

More than 3,000,000 swabs of the throat and nose taken across Britain formed the basis of the public health study. The results showed that the efficacy of the Pfizer and AstraZeneca vaccines had slipped to 75% and 61%, respectively. The decline is compared to the 85% and 68% (respectively) protection that the vaccines offered two weeks after the second dose. The efficacy drop was much more apparent among those aged 35 and above than those below that age range.

The study also showed that fully vaccinated people who catch the virus tend to have a viral load similar to that of the infected unvaccinated. This is a clear deterioration from when the Alpha variant was the most dominant in Britain.

These findings align with an analysis conducted by the US Centres for Disease Control and Prevention (CDC). As a result, President Joe Biden endorsed COVID-19 booster shots for all American adults in a recent speech. Health officials are urging the public to get their third shot eight months after having received the second.

“It’s the best way to protect ourselves from new variants that could arise,” said Biden.

In conjunction with this, Israel released data earlier this week that demonstrated the weakening of Pfizer’s efficacy over time. The data stated that the vaccine was less effective among people aged 65 and above who had been fully vaccinated in January or February.

Pfizer and BioNTech Submit Early Data

Pfizer and BioNTech’s Phase I clinical trial has begun. It is part of the Phase I/II/III programme, which assesses the tolerability, safety, and immunogenicity of the booster (third shot). Phase I evaluates the effect in adult subjects who have had both doses of the vaccination. The data has been submitted to the US Food and Drug Administration (FDA).

Subjects in the latest trial were given a 30µg booster shot of BNT162b2 eight to nine months following their second dose. According to the data, the booster provided increased levels of protection against the Beta and Delta variants compared to when the subject had just two doses.

Pfizer chairman and CEO Albert Bourla said, “The data we’ve seen to date suggests a third dose of our vaccine elicits antibody levels that significantly exceed those seen after the two-dose primary schedule.”

Final Thoughts

CNBC’s ‘Mad Money’ host Jim Cramer pointed out that Pfizer’s stock has increased more than 22% in the past month. Cramer suspects this is due to the mounting evidence that a COVID-19 booster shot is likely needed to combat the virus. As a result, this is leading to increased investor confidence.

According to reports, Pfizer climbed approximately 9% over the four days leading to 17th August. Day-traders sold off more positions than they bought in BioNTech and Moderna.

Legal disclaimer: The material does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instruments. Ebrókerház Ltd accepts no responsibility for any use that may be made of these comments and for any consequences resulting in it. No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. The information presented does not involve any specific investment objectives, financial situation, and needs of any specific person who may receive it. Past performance does not constitute a reliable indicator of future results and future forecasts do not constitute a reliable indicator of future performance.

Please consider that no news or information shared, nor any content included in any other document available in this website, should be understood in any way, either explicitly or implicitly, directly or indirectly as investment advice, recommendation, or a proposal for an investment strategy related to a financial instrument, as these are made available to you solely for information purposes. The data and information disclosed in the news or in the website, or the analyses attached to trading charts, only reflect the result of a technical analysis done by a professionally independent third party and may change without any prior notice.

The clients of eBrókerház Befektetési Szolgáltató Zrt. open orders through the Trade GM Trader Online Trading Platform, the orders will be forwarded to an execution venue defined in our Execution Policy. Trade GM Trader Online Platform is operated by eBrókerház Szolgáltató zrt, which is authorized and regulated by the Hungarian National Bank under the licence numbers III/73.059/2000. and III/73.059-4/2002.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75.42% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. The materials contained on this page are for advertising and marketing purposes only and should not in any way be construed, either explicitly or implicitly, directly or indirectly. as investment advice, recommendation or suggestion of an investment strategy with respect to a financial instrument, in any manner whatsoever. You should make sure that you have sufficient time to manage your investments on an active basis. CDF are derivative financial instruments, which price is derived from the price of the underlying asset or contract to which the CFD refers (for example currencies, commodities, indices, equity, etc.). Derivative financial instruments and related markets can be highly volatile. The prices of CFDs and underlying instrument may fluctuate rapidly over wide ranges and may reflect unforeseeable events or changes in conditions, none of which can be controlled by the client or eBrókerház Befektetési Szolgáltató Zrt. Prices quoted or information may vary and change depending on market conditions. When investing in Company’s Products denominated in a currency other than that of the state in which you reside, the return may increase or decrease as a result of currency fluctuations. Any indication of past performance or simulated past performance included in an advertisement is not a reliable indicator of future results. All names, pictures and personal details of people depicted as traders in advertisements concerning past performance are included for presentation purposes only, and are not the actual traders who have made the transaction detailed in the advertisement (actual details are kept for privacy purposes). All opinions expressed by traders are not actual testimonials but rather are depictive of the actual past performance and trading experience. Any trades depicted are selected from past real successful trades and are not reliable indicator of all customers past or future trades.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75.42% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. X